Article

BioMetals

, Volume 23, Issue 3, pp 399-409

Cancer prevention by bovine lactoferrin: from animal studies to human trial

  • Hiroyuki TsudaAffiliated withNanotoxicology Project, Graduate School of Medical Sciences, Nagoya City UniversityDepartment of Molecular Toxicology, Graduate School of Medical Sciences, Nagoya City University
  • , Takahiro KozuAffiliated withCancer Screening Division, National Cancer Center, Research Center for Cancer Prevention and Screening
  • , Gen IinumaAffiliated withDiagnostic Radiology Division, National Cancer Center Hospital
  • , Yasuo OhashiAffiliated withDepartment of Biostatistics, School of Health Sciences and Nursing, The University of Tokyo
  • , Yutaka SaitoAffiliated withEndoscopy Division, National Cancer Center Hospital
  • , Daizo SaitoAffiliated withEndoscopy Division, National Cancer Center Hospital
  • , Takayuki AkasuAffiliated withColorectal Surgery Division, National Cancer Center Hospital
  • , David B. AlexanderAffiliated withNanotoxicology Project, Graduate School of Medical Sciences, Nagoya City UniversityDepartment of Molecular Toxicology, Graduate School of Medical Sciences, Nagoya City University Email author 
  • , Mitsuru FutakuchiAffiliated withDepartment of Molecular Toxicology, Graduate School of Medical Sciences, Nagoya City University
    • , Katsumi FukamachiAffiliated withDepartment of Molecular Toxicology, Graduate School of Medical Sciences, Nagoya City University
    • , Jiegou XuAffiliated withDepartment of Molecular Toxicology, Graduate School of Medical Sciences, Nagoya City University
    • , Tadao KakizoeAffiliated withNational Cancer Center
    • , Masaaki IigoAffiliated withNanotoxicology Project, Graduate School of Medical Sciences, Nagoya City UniversityDepartment of Molecular Toxicology, Graduate School of Medical Sciences, Nagoya City University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers and, despite improved colonoscopic screening, CRC is a leading cause of death from cancer. Administration of bovine lactoferrin (bLF) suppresses carcinogenesis in the colon and other organs of test animals, and recently it was shown that ingestion of bLF inhibits the growth of adenomatous polyps in human patients. Here we review work which established bLF as an anti-carcinogenic agent in laboratory animals and the results of a clinical trial which demonstrated that bLF can reduce the risk of colon carcinogenesis in humans.

Keywords

Bovine lactoferrin Chemoprevention Colorectal cancer